246 related articles for article (PubMed ID: 24997609)
1. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1.
de la Croix Ndong J; Makowski AJ; Uppuganti S; Vignaux G; Ono K; Perrien DS; Joubert S; Baglio SR; Granchi D; Stevenson DA; Rios JJ; Nyman JS; Elefteriou F
Nat Med; 2014 Aug; 20(8):904-10. PubMed ID: 24997609
[TBL] [Abstract][Full Text] [Related]
2. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I.
Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F
Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497
[TBL] [Abstract][Full Text] [Related]
3. Strengthening bone in neurofibromatosis type 1.
Harrington M
Lab Anim (NY); 2014 Oct; 43(10):338. PubMed ID: 25238512
[No Abstract] [Full Text] [Related]
4. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.
de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F
J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591
[TBL] [Abstract][Full Text] [Related]
5. Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders.
Harmey D; Hessle L; Narisawa S; Johnson KA; Terkeltaub R; Millán JL
Am J Pathol; 2004 Apr; 164(4):1199-209. PubMed ID: 15039209
[TBL] [Abstract][Full Text] [Related]
6. JNK inhibitors increase osteogenesis in Nf1-deficient cells.
Sullivan K; El-Hoss J; Little DG; Schindeler A
Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323
[TBL] [Abstract][Full Text] [Related]
7. [Regulation of bone mineralization by enzymes].
Kubota T; Ozono K
Clin Calcium; 2004 Jun; 14(6):23-7. PubMed ID: 15577050
[TBL] [Abstract][Full Text] [Related]
8. Central role of pyrophosphate in acellular cementum formation.
Foster BL; Nagatomo KJ; Nociti FH; Fong H; Dunn D; Tran AB; Wang W; Narisawa S; Millán JL; Somerman MJ
PLoS One; 2012; 7(6):e38393. PubMed ID: 22675556
[TBL] [Abstract][Full Text] [Related]
9. A Phe377del mutation in ANK leads to impaired osteoblastogenesis and osteoclastogenesis in a mouse model for craniometaphyseal dysplasia (CMD).
Chen IP; Wang L; Jiang X; Aguila HL; Reichenberger EJ
Hum Mol Genet; 2011 Mar; 20(5):948-61. PubMed ID: 21149338
[TBL] [Abstract][Full Text] [Related]
10. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice.
Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC
Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460
[TBL] [Abstract][Full Text] [Related]
11. Antagonistic interactions between osterix and pyrophosphate during cementum formation.
Choi H; Liu Y; Jeong JK; Kim TH; Cho ES
Bone; 2019 Aug; 125():8-15. PubMed ID: 31059863
[TBL] [Abstract][Full Text] [Related]
12. Linked deficiencies in extracellular PP(i) and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression.
Johnson K; Goding J; Van Etten D; Sali A; Hu SI; Farley D; Krug H; Hessle L; Millán JL; Terkeltaub R
J Bone Miner Res; 2003 Jun; 18(6):994-1004. PubMed ID: 12817751
[TBL] [Abstract][Full Text] [Related]
13. Overlapping functions of bone sialoprotein and pyrophosphate regulators in directing cementogenesis.
Ao M; Chavez MB; Chu EY; Hemstreet KC; Yin Y; Yadav MC; Millán JL; Fisher LW; Goldberg HA; Somerman MJ; Foster BL
Bone; 2017 Dec; 105():134-147. PubMed ID: 28866368
[TBL] [Abstract][Full Text] [Related]
14. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice.
Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG
J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of SLC41A1 magnesium transporter promotes mineralization and attenuates magnesium inhibition during osteogenesis of mesenchymal stromal cells.
Tsao YT; Shih YY; Liu YA; Liu YS; Lee OK
Stem Cell Res Ther; 2017 Feb; 8(1):39. PubMed ID: 28222767
[TBL] [Abstract][Full Text] [Related]
16. Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization.
Hessle L; Johnson KA; Anderson HC; Narisawa S; Sali A; Goding JW; Terkeltaub R; Millan JL
Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9445-9. PubMed ID: 12082181
[TBL] [Abstract][Full Text] [Related]
17. Inflammatory cytokines induce a unique mineralizing phenotype in mesenchymal stem cells derived from human bone marrow.
Ferreira E; Porter RM; Wehling N; O'Sullivan RP; Liu F; Boskey A; Estok DM; Harris MB; Vrahas MS; Evans CH; Wells JW
J Biol Chem; 2013 Oct; 288(41):29494-505. PubMed ID: 23970554
[TBL] [Abstract][Full Text] [Related]
18. Basic fibroblast growth factor regulates phosphate/pyrophosphate regulatory genes in stem cells isolated from human exfoliated deciduous teeth.
Nowwarote N; Sukarawan W; Pavasant P; Foster BL; Osathanon T
Stem Cell Res Ther; 2018 Dec; 9(1):345. PubMed ID: 30526676
[TBL] [Abstract][Full Text] [Related]
19. Potential role of PC-1 expression and pyrophosphate elaboration in the molecular etiology of the FGFR-associated craniosynostosis syndromes.
Hatch NE
Orthod Craniofac Res; 2007 May; 10(2):53-8. PubMed ID: 17552941
[TBL] [Abstract][Full Text] [Related]
20. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia.
Kishnani PS; Rockman-Greenberg C; Rauch F; Bhatti MT; Moseley S; Denker AE; Watsky E; Whyte MP
Bone; 2019 Apr; 121():149-162. PubMed ID: 30576866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
